SynthesisInternational journal of urology : official journal of the Japanese Urological Association2025
Survivorship Post-Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: A Systematic Review.
Synthesis in International journal of urology : official journal of the Japanese Urological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Re-evaluating the 'gonadal ganglion': anatomical insights into intermesenteric ganglia and gonadal innervation.Surgical and radiologic anatomy : SRA · 2025Article
- Editorial Comment on Survivorship Postretroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: A Systematic Review.International journal of urology : official journal of the Japanese Urological Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRetroperitoneal lymph node dissection (RPLND) may be considered after chemotherapy or as primary treatment in patients with metastatic testicular cancer. We aimed to perform a systematic review to analyze outcomes in survivors across the domains of sexual, physical, and psychological function. It is the first systematic review of outcomes of survivorship following RPLND.
methodsA systematic review was performed as per PRISMA guidelines. Outcomes were extracted from studies meeting the inclusion criteria and were analyzed.
resultsIn total, there were 11 studies included with 1086 patients. Of these, 80.5% had stage 1 disease and 63.1% had nerve-sparing surgery. Clavien-Dindo 1-2 post-operative complications were reported in 14.1% of cases and Clavien-Dindo 3-5 in 4.5%. There was a 7.0% recurrence rate. Sexual impairment including hypospermia, dry ejaculation, and erectile dysfunction was more prevalent among patients who had non-nerve-sparing procedures. Primary robotic surgery was reported to decrease the systemic chemotherapy burden in patients. Physical, emotional, social functioning, and global quality of life were significantly better in minimally invasive surgery compared to open RPLND.
conclusionRPLND is a viable treatment approach and may be considered at multidisciplinary discussions for patients with metastatic testicular cancer. Minimally invasive surgery appears to have better sexual, physical, and psychological outcomes compared to open surgery, with low rates of perioperative complications and acceptable early oncologic outcomes. However, these patients may have been carefully selected and, therefore, are more likely to have favorable outcomes. Sexual dysfunction is a possible complication, and patients should be thoroughly counseled about the risks and benefits of RPLND.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.